MET and cancer: To compare the efficacy of a specific MET TKI and neutralizing antibody in inhibiting cancer cells with these two types of MET activation, MKN45, MHCC97H, U87 and JHH5 cells were treated by INC280 or MetMab at various concentrations for 72 h and tested for cell viability using the Cell-titer Glo assay (Fig. 1a, b).